Inclisiran 284mg/1.5mL Injection$1,580.00
1–9 boxes
$1,580.00 each
10–24 boxes
8% off
25+ boxes
10% off
Inclisiran 284mg/1.5mL Injection
SKU GME1117Cardiac Care
Product Introduction
Inclisiran 284mg/1.5mL is a long-acting LDL-cholesterol-lowering injection for primary hypercholesterolaemia or mixed dyslipidaemia. It is used alongside dietary measures, usually with statin-based treatment when additional LDL reduction is needed.
How to use
A healthcare professional gives the injection under the skin of the abdomen, thigh or upper arm. The second dose is given three months after the first, followed by an injection every six months. Avoid injecting into inflamed, infected or otherwise damaged skin.
How it works
Inclisiran is a small interfering RNA that reduces production of PCSK9 in liver cells. More LDL receptors then remain available to remove LDL cholesterol from the blood.
Side effects
Pain, redness or rash at the injection site are the principal common adverse effects. A serious allergic reaction is uncommon but needs immediate treatment if facial swelling or breathing difficulty develops.
Important information
Continue the other cholesterol-lowering medicines that form part of the regimen rather than stopping them after the injection. LDL measurements assess the response. Pregnancy, breastfeeding and severe liver disease require individual assessment before further dosing.
Uses
- Primary hypercholesterolaemia, including heterozygous familial disease, and mixed dyslipidaemia when additional LDL lowering is required or statin intolerance limits treatment.
Benefits
Provides sustained additional LDL-cholesterol reduction with injections every six months after the initial and three-month doses, helping maintain cholesterol control between visits.
Is inclisiran a statin?
No. Statins inhibit cholesterol synthesis, while inclisiran reduces PCSK9 production through RNA interference. The different mechanisms allow them to be used together.
What happens if an injection is more than three months late?
The schedule generally restarts with a dose now, another at three months and then six-monthly doses. A shorter delay is usually managed by giving the missed dose and continuing the original schedule.
Does it remove the need to monitor cholesterol?
No. LDL testing shows how much additional reduction has occurred and whether the overall regimen is reaching its target.
Does a large LDL reduction guarantee no heart attack?
No. LDL lowering addresses an important risk factor, but cardiovascular risk also depends on blood pressure, diabetes, smoking and existing vascular disease.
LDL cholesterol: cholesterol carried in low-density lipoproteins. PCSK9: protein reducing availability of LDL receptors. siRNA: small interfering RNA that suppresses a specific messenger RNA. Dyslipidaemia: abnormal blood-fat levels. Familial hypercholesterolaemia: inherited tendency to high LDL cholesterol.; AR: Inclisiran 284mg/1.5mL حقن; FR: Inclisiran 284mg/1.5mL préparation injectable; PT: Inclisiran 284mg/1.5mL injetável; ES: Inclisiran 284mg/1.5mL inyectable; RU: Inclisiran 284mg/1.5mL инъекционная форма; ID: Inclisiran 284mg/1.5mL injeksi; VI: Inclisiran 284mg/1.5mL thuốc tiêm; MS: Inclisiran 284mg/1.5mL suntikan; TL: Inclisiran 284mg/1.5mL iniksyon; ZH-SG: Inclisiran 284mg/1.5mL 注射剂